Orion Oyj (HEL:ORNAV)

Market Cap	8.91B
Revenue (ttm)	1.59B
Net Income (ttm)	347.40M
Shares Out	n/a
EPS (ttm)	2.47
PE Ratio	25.64
Forward PE	22.31
Dividend	1.64 (2.62%)
Ex-Dividend Date	Oct 15, 2025

Volume	8,400
Average Volume	9,801
Open	62.60
Previous Close	62.30
Day's Range	62.30 - 63.30
52-Week Range	39.05 - 64.10
Beta	0.37
RSI	63.40
Earnings Date	Jul 18, 2025

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid art...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1917
• Employees: 3,880
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: ORNAV

Financial Performance

In 2024, Orion Oyj's revenue was 1.54 billion, an increase of 29.65% compared to the previous year's 1.19 billion. Earnings were 329.90 million, an increase of 52.17%.